ScoreWhy is Pacific Biosciences of California, Inc. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -225.21% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -43.08
2
The company declared very negative results in Mar'25 after flat results in Dec'24
- ROCE(HY) Lowest at -213.45%
- DEBT-EQUITY RATIO (HY) Highest at 7,906.45 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 1.61%, its profits have fallen by -109%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -1.02% over the previous quarter and currently hold 7.32% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Underperformed the market in the last 1 year
- The stock has generated a return of 1.61% in the last 1 year, much lower than market (S&P 500) returns of 11.87%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Pacific Biosciences of California, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Pacific Biosciences of California, Inc.
1.61%
-0.37
90.84%
S&P 500
11.87%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.19%
EBIT Growth (5y)
-225.21%
EBIT to Interest (avg)
-43.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.33
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.04%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
76.78
EV to EBIT
-1.99
EV to EBITDA
-7.12
EV to Capital Employed
1.62
EV to Sales
6.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-81.44%
ROE (Latest)
-9768.14%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -92.15 MM
RAW MATERIAL COST(Y)
Fallen by -184.42% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 8.76 times
NET SALES(Q)
Highest at USD 44.65 MM
PRE-TAX PROFIT(Q)
At USD -40.17 MM has Grown at 70.46%
NET PROFIT(Q)
At USD -40.37 MM has Grown at 70.04%
-3What is not working for the Company
ROCE(HY)
Lowest at -213.45%
DEBT-EQUITY RATIO
(HY)
Highest at 7,906.45 %
Here's what is working for Pacific Biosciences of California, Inc.
Operating Cash Flow
Highest at USD -92.15 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 44.65 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD -40.17 MM has Grown at 70.46%
over average net sales of the previous four periods of USD -135.97 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -40.37 MM has Grown at 70.04%
over average net sales of the previous four periods of USD -134.74 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 8.76 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -184.42% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Pacific Biosciences of California, Inc.
Debt-Equity Ratio
Highest at 7,906.45 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
